Abrysvo: Pfizer Canada's newly publicly funded vaccine a step towards national RSV prevention in older adults

19 September 2024 -  Today, Pfizer Canada announced that Abrysvo has been selected as the publicly funded vaccine for the ...

Read more →

Valneva submits label extension applications for its chikungunya vaccine Ixchiq to EMA and Health Canada

18 September 2024 - To potentially include adolescents and antibody persistence up to two years. ...

Read more →

Biogen's new drug submission for omaveloxolone accepted for priority review by Health Canada for the treatment of Friedreich's ataxia

17 September 2024 - If approved, omaveloxolone would be the only disease specific treatment option for patients living with this progressive ...

Read more →

Dupixent (dupilumab injection) approved in Canada for the treatment of children aged 1 year and older with eosinophilic oesophagitis

12 September 2024 - This is the ninth indication for Dupixent in Canada and its second in gastroenterology. ...

Read more →

Health Canada approves Keytruda as monotherapy for the treatment of adult and paediatric patients with unresectable or metastatic microsatellite instability-high or mismatch repair deficient solid tumours that have progressed following prior treatment and who have no satisfactory alternative treatment options

12 September 2024  - Merck announced that Health Canada has granted approval of Keytruda (pembrolizumab), Merck's anti-PD-1 therapy, as a monotherapy ...

Read more →

Merck Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Welireg (belzutifan)

5 September 2024 - Merck announced that it has successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Welireg (belzutifan) on ...

Read more →

Health Canada approves Cabtreo (clindamycin phosphate, adapalene and benzoyl peroxide) triple combination topical treatment for acne vulgaris in patients 12 years of age and older

11 September 2024 - Bausch Health today announced the approval by Health Canada of Cabtreo (clindamycin phosphate, adapalene and benzoyl ...

Read more →

Health Canada approves AbbVie's Constella (linaclotide) for the treatment of functional constipation in paediatric patients 6 to 17 years of age

10 September 2024 - Submission is based on positive Phase 3 study data demonstrating linaclotide (72 mcg) resulted in increases ...

Read more →

Today’s the day: we are officially Canada’s Drug Agency

5 September 2024 - We are expanding on our existing mandate and functions — which span drugs, medical devices, and clinical ...

Read more →

Winrevair (sotatercept) is now authorised for use in Canada for adults with pulmonary arterial hypertension

4 September 2024 - Merck announced that Winrevair (sotatercept) is now authorised for use in Canada in combination with standard ...

Read more →

Lilly Canada and the pan-Canadian Pharmaceutical Alliance successfully complete negotiations for Omvoh (mirikizumab) for adults with moderately to severely active ulcerative colitis

3 September 2024 - Eli Lilly Canada announced today that it successfully completed negotiations with the pan-Canadian Pharmaceutical Alliance for Omvoh ...

Read more →

Kye Pharmaceuticals announces approval in Canada for ACCRUFeR (ferric maltol) for the treatment of iron deficiency anaemia in adult patients

27 August 2024 - Kye Pharmaceuticals today announced that ACCRUFeR (ferric maltol) has received market authorisation as a prescription medicine in ...

Read more →

Padcev (enfortumab vedotin) in combination with pembrolizumab approved by Health Canada to treat advanced bladder cancer

22 August 2024 - Padcev plus pembrolizumab approved based on EV-302 trial. ...

Read more →

Henlius trastuzumab receives approval in Canada

22 August 2024 - Shanghai Henlius Biotech announced that the company's business partner, Accord Healthcare has received marketing approval (Notice of ...

Read more →

Health Canada approves Keytruda for the treatment of adult patients with unresectable locally advanced or metastatic urothelial cancer with no prior systemic therapy for metastatic urothelial cancer, in combination with enfortumab vedotin

22 August 2024 - Approval is based on the Phase 3 KEYNOTE-A39 trial. ...

Read more →